Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

PURPOSE: To evaluate safety of TAS-102 administered twice daily (bid) on days 1–5 and 8–12 of a 4-week cycle, confirm feasibility of the Japanese recommended dose (RD), 35 mg/m(2), in Western patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapies, and describe prelim...

Descripción completa

Detalles Bibliográficos
Autores principales: Bendell, Johanna C., Rosen, Lee S., Mayer, Robert J., Goldman, Jonathan W., Infante, Jeffrey R., Benedetti, Fabio, Lin, Donghu, Mizuguchi, Hirokazu, Zergebel, Christopher, Patel, Manish R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612319/
https://www.ncbi.nlm.nih.gov/pubmed/26370544
http://dx.doi.org/10.1007/s00280-015-2850-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612319/
https://www.ncbi.nlm.nih.gov/pubmed/26370544
http://dx.doi.org/10.1007/s00280-015-2850-4

Ejemplares similares